about
Flavonoids in Inflammatory Bowel Disease: A ReviewIntestinal barrier in inflammatory bowel diseaseConstitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosisSubstance P modulates colitis-associated fibrosisCD137 facilitates the resolution of acute DSS-induced colonic inflammation in miceDistinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis.Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis.Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in ColitisThe nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cellsSUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.Expression of PPAR γ in intestinal epithelial cells is dispensable for the prevention of colitis by dietary abscisic acid.Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation.Importance of disrupted intestinal barrier in inflammatory bowel diseases.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Future therapeutic approaches for inflammatory bowel diseases.Cellular and molecular mechanisms of autoimmune disease.Immune responses triggering colitis and colitis-associated carcinoma.Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 AxisInflammatory Bowel Disease Associated Colorectal Neoplasia.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Plasma-induced signatures reveal an extracellular milieu possessing an immunoregulatory bias in treatment-naive paediatric inflammatory bowel disease.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.The role of UVR and vitamin D on T cells and inflammatory bowel disease.High-resolution gene expression profiling using RNA sequencing in patients with inflammatory bowel disease and in mouse models of colitis.Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis.Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases.Serum metabolic profiling in inflammatory bowel disease.Hearing Loss in Patients with Inflammatory Bowel Disease.Targeting the innate immune system in pediatric inflammatory bowel disease.Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis.Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-κB and JNK activation in intestinal epithelial cells.Understanding the Pathogenesis of Endometriosis: Gene Mapping StudiesMicrobiota-sensitive epigenetic signature predicts inflammation in Crohn's disease
P2860
Q26748883-7CF2361E-D4F3-4C3D-A10E-B2F5392E920DQ27023724-94B18E7D-3146-4144-A54E-E679F38A2A33Q33802845-4614DDFE-76D6-40C5-9051-B19D0296BA44Q34254416-E2E40B51-20D3-4790-B07F-6347FCCBC865Q34984338-E09A5695-D5CE-412E-8670-AA6130F2EEDCQ35187940-AAEC053F-FECC-4710-8D0B-9D124F97DAD2Q35951975-65F60C84-3914-4AAC-BEBF-7B525F70A103Q36185631-0E82F53E-D42B-4485-AA35-73D317B60E1FQ36283368-DF63DD07-FEC6-4178-AE2F-5E2E25E0AB97Q36590355-2FC0B544-B66F-490A-9416-CA8354E3EEAEQ36800644-75D87668-5A92-4D3C-9BD4-58696A73F5A3Q36953391-0DED12C1-5727-4D93-8468-814ABE9FEC63Q37358329-59854E0C-D9B8-4855-AC89-958506C2202CQ37781315-8538AE27-813A-4EC4-AFB2-ED4B1E3F33B4Q37847059-C07A8B6B-4085-4778-B350-9C83A96C36A5Q37870435-EC032608-6244-45F6-9CF8-417D010DEF05Q37959331-04625A42-47B6-465E-BA1F-47AD679098EEQ37989833-5D24CB92-2ADC-4FE3-9B67-B17C4390147FQ38002856-D13AE760-A36A-40E7-B432-D733D2920F9AQ38201722-C21F3F4B-4D33-4D69-B8F0-3DEF666FAB82Q38293774-48865AA5-D73B-47B3-A95C-3DE45DF74416Q38453755-578DB429-2607-4D06-AD57-94D50FF35395Q38735477-7D22FBA8-0AE4-4225-90CB-5D5F6ADE0612Q39314275-478ADB23-CD6B-4781-9B4B-D88988F1CB8DQ41185159-E1273182-4250-47D9-80C8-EB0A58D39C1EQ41221924-CA47C2AD-17C9-4E2B-B0AD-C71682BF26F5Q42223966-E17A8F14-D898-4B50-AAB3-24F97472CBEEQ46700871-7850B8EA-AD9B-4E24-BA54-8269C8146F01Q47979606-843CCB49-6F71-428E-8637-57224F164F9EQ49162097-79752575-D12A-4161-9A2A-7F5472D810ACQ50316773-A1F1B3E8-A63B-4E03-B738-A2DBA97BE5A1Q52898201-3D151C46-EE08-429A-A4D9-C471F9031513Q54508822-682B6087-EEEA-4E5E-BBB0-E3D1ED222853Q54624599-3AC78CE8-2266-4161-B715-9601845210FFQ57611277-8AECFF9E-4F43-4331-B4F7-F96EFC3E05DCQ59125547-0A2C8E15-2C7B-4BCB-AC00-ED1B7AD23975
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Insights into IBD Pathogenesis.
@ast
Insights into IBD Pathogenesis.
@en
type
label
Insights into IBD Pathogenesis.
@ast
Insights into IBD Pathogenesis.
@en
prefLabel
Insights into IBD Pathogenesis.
@ast
Insights into IBD Pathogenesis.
@en
P2860
P1476
Insights into IBD Pathogenesis.
@en
P2093
David Q Shih
Stephan R Targan
P2860
P2888
P304
P356
10.1007/S11894-009-0072-9
P577
2009-12-01T00:00:00Z
P5875
P6179
1052856323